HIGHLIGHTS
- who: Lei Gao et al. from the The First Affiliated Hospital of Yangtze University, Jingzhou, China have published the research work: Immunotherapeutic Strategies for Head and Neck Squamous Cell Carcinoma (HNSCC): Current Perspectives and Future Prospects, in the Journal: Vaccines 2022, 1272 of 16/08/2018
- what: The sample size of current trials is small for the following reasons: 1. most neoantigens are derived from unique mutations that are not shared between different patients, requiring personalized treatment; 2. the cost of preparing neoantigen vaccines is high and unaffordable for many families, and 3. the vaccine . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.